Olivier Bohuon Joins Pierre Fabre

By Groupe Pierre Fabre, PRNE
Thursday, July 1, 2010

CASTRES, France, July 2, 2010 - Olivier Bohuon will be replacing Jean-Pierre Garnier as Chief
Executive Officer at Pierre Fabre Group starting September 1, 2010.

Until now, Olivier Bohuon, 51, was Executive Vice-President of
the Abbott Corporation and President of its pharmaceutical division. As such,
he ran the group's entire pharmaceutical activities from Chicago ($22 billion
in sales). In 2003, he was named the group's President for European
operations and later became President of Abbott International.

Prior to that, before beginning his career at Roussel Uclaf in
Morocco (and later in the Middle East), Olivier Bohuon was the Marketing
Director and then the Operations Director of Glaxo France (1991-1995), CEO
and then President of SmithKline Beecham Laboratories (1995-2001), and
Director of GlaxoSmithKline's Commercial Operations, Europe (2001-2003).

Olivier Bohuon holds a Doctor of Pharmacy as well as an HEC
MBA.

He is a member of the National Pharmacy Academy and the
Academy of Technologies and is a knight of the Légion d'Honneur.

After an international career, at the end of which he was
entrusted with the highest operational responsibilities within the
pharmaceutical sector, Olivier Bohuon chose to return to France to pursue his
career there.

In addition to his duties as the group's CEO, he will also act
as President of Pierre Fabre Medicament.

When his arrival at Pierre Fabre was announced, Olivier BOHUON
stated, "I will head the group in close collaboration with his chairman and
founder and we will jointly paving the future; my action will be registered
in the long run."

About the Pierre Fabre group:

The Pierre Fabre Group, the second largest independent French
pharmaceutical company and leader in the field of in-pharmacy
dermo-cosmetics, employs about 10,000 people worldwide, including 1,400 R&D
staff, and generates a sales turnover of EUR1.8 billion.

In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to
R&D in four priority therapeutic areas in public health: oncology, central
nervous system, dermatology, cardio-vascular/metabolism.

To learn more about Pierre Fabre, please refer to
www.pierre-fabre.com.

Press Contact : Djamila Hazene-Kedjem, djamila.hazene.kedjem at pierre-fabre.com , +33(0)1-49-10-81-12 / +33(6)-89-45-87-95

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :